N‐methyl‐d‐aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia: TDT and case‐control analyses

The N‐methyl‐d‐aspartate glutamate receptors (NMDAR) act in the CNS as regulators of the release of neurotransmitters such as dopamine, noradrenaline, acetylcholine, and GABA. It has been suggested that a weakened glutamatergic tone increases the risk of sensory overload and of exaggerated responses in the monoaminergic system, which is consistent with the symptomatology of schizophrenia. We studied two silent polymorphisms in GRIN1. GRIN1/1 is a G/C substitution localized on the 5′ untranslated region; GRIN1/10 is an A/G substitution localized in exon 6 of GRIN1. Minor allele frequencies in our sample were calculated to be 0.05 and 0.2 respectively. We genotyped 86 nuclear families and 91 ethnically matched case‐control pairs. Both samples were collected from the Toronto area. We tested the hypothesis that GRIN1 polymorphisms were associated with schizophrenia using the transmission disequilibrium test (TDT) and comparing allele frequencies between cases and controls. The results are as follows: GRIN1/1: χ2 = 2.19, P = 0.14; GRIN1/10: χ2 = 1.5, P = 0.22. For the case‐control sample: GRIN1/1: χ2 = 0.013, P = 0.908; GRIN1/10: χ2 = 0.544, P = 0.461. No significant results were obtained. Haplotype analyses showed a borderline significant result for the 2,1 haplotype (χ2 = 3.86, P‐value = 0.049). An analysis of variance (ANOVA) to evaluate the association between genetic makeup and age at onset was performed, with no significant results: GRIN1/1, F[df = 2] = 0.42, P‐value = 0.659; GRIN1/10, F[df = 2] = 0.16, P‐value = 0.853. We are currently collecting additional samples to increase the power of the analyses. © 2003 Wiley‐Liss, Inc.

[1]  Mark Farrant,et al.  NMDA receptor subunits: diversity, development and disease , 2001, Current Opinion in Neurobiology.

[2]  D. B. Berman,et al.  Identification of single nucleotide polymorphisms (SNPs) and other sequence changes and estimation of nucleotide diversity in coding and flanking regions of the NMDAR1 receptor gene in schizophrenic patients , 2001, Molecular Psychiatry.

[3]  S. Nakanishi,et al.  Structures and properties of seven isoforms of the NMDA receptor generated by alternative splicing. , 1992, Biochemical and biophysical research communications.

[4]  H. Betz,et al.  Evidence for a Tetrameric Structure of Recombinant NMDA Receptors , 1998, The Journal of Neuroscience.

[5]  P. Seeburg,et al.  Regional and developmental heterogeneity in splicing of the rat brain NMDAR1 mRNA , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[6]  B. Sakmann,et al.  Developmental and regional expression in the rat brain and functional properties of four NMDA receptors , 1994, Neuron.

[7]  S. Nakanishi,et al.  Differential expression of five N‐methyl‐D‐aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats , 1994, The Journal of comparative neurology.

[8]  P. V. Rayudu,et al.  Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A , 1998, Nature.

[9]  Marc G Caron,et al.  Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia , 1999, Cell.

[10]  Susumu Tonegawa,et al.  Whisker-related neuronal patterns fail to develop in the trigeminal brainstem nuclei of NMDAR1 knockout mice , 1994, Cell.

[11]  A. Awad,et al.  Psychopharmacology: The Fourth Generation of Progress , 1998, CNS Spectrums.

[12]  H. H. Kornhuber,et al.  Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.

[13]  A Carlsson,et al.  Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. , 2001, Annual review of pharmacology and toxicology.

[14]  A. Kuryatov,et al.  Mutational analysis of the glycine-binding site of the NMDA receptor: Structural similarity with bacterial amino acid-binding proteins , 1994, Neuron.

[15]  J. Nurnberger,et al.  A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. , 1991, Nucleic acids research.

[16]  J. Meador-Woodruff,et al.  Glutamate receptor expression in schizophrenic brain , 2000, Brain Research Reviews.

[17]  G. Rumbaugh,et al.  Distinct Synaptic and Extrasynaptic NMDA Receptors in Developing Cerebellar Granule Neurons , 1999, The Journal of Neuroscience.

[18]  S. Vicini,et al.  Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors. , 1998, Journal of neurophysiology.

[19]  J. Connor,et al.  Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death , 1994, Neuron.

[20]  R. Dingledine,et al.  The glutamate receptor ion channels. , 1999, Pharmacological reviews.

[21]  T. Arinami,et al.  Mutation analysis of the N-methyl-d-aspartate receptor NR1 subunit gene (GRIN1) in schizophrenia , 2000, Neuroscience Letters.

[22]  M. Hollmann Structure of Ionotropic Glutamate Receptors , 1999 .

[23]  D. Colquhoun,et al.  Identification of Amino Acid Residues of the NR2A Subunit That Control Glutamate Potency in Recombinant NR1/NR2A NMDA Receptors , 1998, The Journal of Neuroscience.

[24]  S. Nakanishi,et al.  Molecular cloning and characterization of the rat NMDA receptor , 1991, Nature.

[25]  C. Falk,et al.  Haplotype relative risks: an easy reliable way to construct a proper control sample for risk calculations , 1987, Annals of human genetics.

[26]  W. Ewens,et al.  Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). , 1993, American journal of human genetics.